DAFNA Capital Management
LOS ANGELES, CAfiles as DAFNA Capital Management LLC
$524m in 88 US stocks at the end of 30 June 2026. The top 10 are 56.2% of the money. It changed about 23.8% of the portfolio this quarter.
Value
$524m
Stocks
88
Top 10 share
56.2%
Turnover
23.8%
What changed this quarter
New
Bought for the first time this quarter.
- Ascendis Pharma A/SASND2.5% of the fund
- Kymera TherapeuticsKYMR0.6% of the fund
- Adlai NortyeANL0.5% of the fund
- Nervgen PharmaNGEN0.4% of the fund
- Atrium TherapeuticsRNA0.3% of the fund
- Eupraxia PharmaceuticalsEPRX0.3% of the fund
- Design TherapeuticsDSGN0.3% of the fund
- Corbus Pharmaceuticals HoldingsCRBP0.2% of the fund
- Seaport TherapeuticsSPTX0.1% of the fund
- Artiva BiotherapeuticsARTV0.1% of the fund
- ScynexisSCYX0.1% of the fund
- Editas MedicineEDIT0.1% of the fund
- Q32 BioQTTB<0.1% of the fund
- Nuvectis PharmaNVCT<0.1% of the fund
- Tenaya TherapeuticsTNYA<0.1% of the fund
- enGene TherapeuticsENGN<0.1% of the fund
- KardiganKARD<0.1% of the fund
Added
Bought more of a stock they already held.
- Nektar TherapeuticsNKTR4.2% of the fund+93%
- Denali TherapeuticsDNLI3.6% of the fund+132%
- IDEAYA BiosciencesIDYA3.5% of the fund+4%
- InsuletPODD1.8% of the fund+469%
- Edgewise TherapeuticsEWTX1.8% of the fund+102%
- Syndax PharmaceuticalsSNDX1.4% of the fund+54%
- Allogene TherapeuticsALLO0.8% of the fund+46%
- OrthopediatricsKIDS0.7% of the fund+98%
- Helus PharmaHELP0.6% of the fund+3%
- NeurogeneNGNE0.5% of the fund+57%
- Aquestive TherapeuticsAQST0.5% of the fund+75%
- Maze TherapeuticsMAZE0.4% of the fund+86%
- AnnexonANNX0.3% of the fund+153%
- CytomX TherapeuticsCTMX0.3% of the fund+91%
- ARS PharmaceuticalsSPRY0.3% of the fund+18%
- Mineralys TherapeuticsMLYS0.2% of the fund+16%
- ADC Therapeutics SAADCT<0.1% of the fund+7%
Cut
Sold some of their stake.
- Revolution MedicinesRVMD20.1% of the fund-3%
- Spdr Series TrustXBI5.9% of the fund-38%
- COMPASS PathwaysCMPS5.4% of the fund-17%
- CytokineticsCYTK2.8% of the fund-21%
- Neurocrine BiosciencesNBIX1.9% of the fund-18%
- AxogenAXGN1.8% of the fund-16%
- Bicara TherapeuticsBCAX1.6% of the fund-32%
- Ishares TRIBB1.5% of the fund-31%
- Alkermes plc.ALKS1.0% of the fund-27%
- Biocryst PharmaceuticalsBCRX0.8% of the fund-7%
- ProQR TherapeuticsPRQR0.5% of the fund-2%
- Align TechnologyALGN0.5% of the fund-7%
- BiohavenBHVN0.4% of the fund-84%
- Ultragenyx PharmaceuticalRARE0.3% of the fund-23%
- Fate TherapeuticsFATE0.3% of the fund-5%
- Kura OncologyKURA0.3% of the fund-49%
- ImmaticsIMTX0.2% of the fund-48%
- MBX BiosciencesMBX0.1% of the fund-93%
- CompugenCGEN<0.1% of the fund-35%
- iBioIBIO<0.1% of the fund-12%
- Verrica PharmaceuticalsVRCA<0.1% of the fund-85%
Sold out
Sold their entire stake.
- DAY One Biopharmaceuticals I-100%
- Kalvista Pharmaceuticals-100%
- Ascendis Pharma A/SASND-100%
- Fulcrum TherapeuticsFULC-100%
- Engene Holdings-100%
- Scynexis-100%
- Oric PharmaceuticalsORIC-100%
- Zenas BioPharmaZBIO-100%
- NewAmsterdam PharmaNAMS-100%
- Karyopharm TherapeuticsKPTI-100%
- Neumora TherapeuticsNMRA-100%
Holdings
- Spdr Series TrustXBI
- Share
- 5.9%
- Value
- $31m
- Shares
- 196,505
-38%
- Ishares TRIBB
- Share
- 1.5%
- Value
- $8m
- Shares
- 42,595
-31%
- Lakefront Biotherapeutics NVLKFT
- Share
- 0.7%
- Value
- $4m
- Shares
- 130,175
Held
- Helus PharmaHELP
- Share
- 0.6%
- Value
- $3m
- Shares
- 514,061
+3%
- Adlai NortyeANL
- Share
- 0.5%
- Value
- $3m
- Shares
- 239,553
New
- Structure TherapeuticsGPCR
- Share
- 0.5%
- Value
- $2m
- Shares
- 46,500
Held
- Nervgen PharmaNGEN
- Share
- 0.4%
- Value
- $2m
- Shares
- 1,050,000
New
- Atrium TherapeuticsRNA
- Share
- 0.3%
- Value
- $2m
- Shares
- 128,000
New
- Eupraxia PharmaceuticalsEPRX
- Share
- 0.3%
- Value
- $1m
- Shares
- 225,600
New
- Seaport TherapeuticsSPTX
- Share
- 0.1%
- Value
- $703,728
- Shares
- 32,400
New
- Biontech SEBNTX
- Share
- 0.1%
- Value
- $651,350
- Shares
- 7,000
Held
- Autolus TherapeuticsAUTL
- Share
- <0.1%
- Value
- $286,906
- Shares
- 179,316
Held
- Bicycle TherapeuticsBCYC
- Share
- <0.1%
- Value
- $273,446
- Shares
- 64,492
Held
- KardiganKARD
- Share
- <0.1%
- Value
- $119,250
- Shares
- 5,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Revolution MedicinesRVMD | 20.1% | $105m | 562,630 | -3% |
| Spdr Series TrustXBI | 5.9% | $31m | 196,505 | -38% |
| COMPASS PathwaysCMPS | 5.4% | $28m | 2,011,952 | -17% |
| StereotaxisSTXS | 4.5% | $24m | 13,680,554 | Held |
| Nektar TherapeuticsNKTR | 4.2% | $22m | 318,380 | +93% |
| Denali TherapeuticsDNLI | 3.6% | $19m | 739,014 | +132% |
| IDEAYA BiosciencesIDYA | 3.5% | $19m | 497,240 | +4% |
| AtriCureATRC | 3.2% | $17m | 597,431 | Held |
| Xenon PharmaceuticalsXENE | 2.9% | $15m | 250,772 | Held |
| CytokineticsCYTK | 2.8% | $15m | 171,998 | -21% |
| Arcus BiosciencesRCUS | 2.6% | $14m | 441,829 | Held |
| Ascendis Pharma A/SASND | 2.5% | $13m | 48,469 | New |
| Neurocrine BiosciencesNBIX | 1.9% | $10m | 57,769 | -18% |
| AxogenAXGN | 1.8% | $10m | 208,960 | -16% |
| InsuletPODD | 1.8% | $9m | 61,870 | +469% |
| Edgewise TherapeuticsEWTX | 1.8% | $9m | 226,819 | +102% |
| Bicara TherapeuticsBCAX | 1.6% | $8m | 284,955 | -32% |
| Ishares TRIBB | 1.5% | $8m | 42,595 | -31% |
| Syndax PharmaceuticalsSNDX | 1.4% | $7m | 335,255 | +54% |
| MapLight TherapeuticsMPLT | 1.2% | $6m | 171,006 | Held |
| Larimar TherapeuticsLRMR | 1.2% | $6m | 2,008,164 | Held |
| Century TherapeuticsIPSC | 1.1% | $6m | 2,400,458 | Held |
| DexcomDXCM | 1.1% | $6m | 86,279 | Held |
| ImmunovantIMVT | 1.1% | $6m | 149,524 | Held |
| InogenINGN | 1.0% | $5m | 845,179 | Held |
| Tandem Diabetes CareTNDM | 1.0% | $5m | 355,208 | Held |
| Alkermes plc.ALKS | 1.0% | $5m | 101,266 | -27% |
| Stoke TherapeuticsSTOK | 0.8% | $4m | 130,875 | Held |
| Allogene TherapeuticsALLO | 0.8% | $4m | 2,000,000 | +46% |
| Biocryst PharmaceuticalsBCRX | 0.8% | $4m | 400,248 | -7% |
| Lakefront Biotherapeutics NVLKFT | 0.7% | $4m | 130,175 | Held |
| OrthopediatricsKIDS | 0.7% | $4m | 189,130 | +98% |
| Helus PharmaHELP | 0.6% | $3m | 514,061 | +3% |
| Rapport TherapeuticsRAPP | 0.6% | $3m | 75,000 | Held |
| Kymera TherapeuticsKYMR | 0.6% | $3m | 27,000 | New |
| ProQR TherapeuticsPRQR | 0.5% | $3m | 1,530,361 | -2% |
| NeurogeneNGNE | 0.5% | $3m | 89,032 | +57% |
| Adlai NortyeANL | 0.5% | $3m | 239,553 | New |
| PROCEPT BioRoboticsPRCT | 0.5% | $3m | 120,000 | Held |
| Aquestive TherapeuticsAQST | 0.5% | $3m | 645,915 | +75% |
| Celldex TherapeuticsCLDX | 0.5% | $3m | 68,518 | Held |
| Structure TherapeuticsGPCR | 0.5% | $2m | 46,500 | Held |
| Align TechnologyALGN | 0.5% | $2m | 14,000 | -7% |
| Viking TherapeuticsVKTX | 0.4% | $2m | 59,516 | Held |
| Nervgen PharmaNGEN | 0.4% | $2m | 1,050,000 | New |
| BiohavenBHVN | 0.4% | $2m | 137,593 | -84% |
| Maze TherapeuticsMAZE | 0.4% | $2m | 65,000 | +86% |
| AlectorALEC | 0.3% | $2m | 908,351 | Held |
| Lexeo TherapeuticsLXEO | 0.3% | $2m | 377,059 | Held |
| Profound MedicalPROF | 0.3% | $2m | 260,360 | Held |
| Atrium TherapeuticsRNA | 0.3% | $2m | 128,000 | New |
| AnnexonANNX | 0.3% | $2m | 297,812 | +153% |
| CytomX TherapeuticsCTMX | 0.3% | $2m | 438,407 | +91% |
| Ultragenyx PharmaceuticalRARE | 0.3% | $2m | 47,100 | -23% |
| Eupraxia PharmaceuticalsEPRX | 0.3% | $1m | 225,600 | New |
| Design TherapeuticsDSGN | 0.3% | $1m | 102,600 | New |
| Fate TherapeuticsFATE | 0.3% | $1m | 525,000 | -5% |
| MediWoundMDWD | 0.3% | $1m | 94,405 | Held |
| Kura OncologyKURA | 0.3% | $1m | 120,568 | -49% |
| ARS PharmaceuticalsSPRY | 0.3% | $1m | 164,285 | +18% |
| Mineralys TherapeuticsMLYS | 0.2% | $1m | 44,490 | +16% |
| ImmaticsIMTX | 0.2% | $1m | 116,960 | -48% |
| TELA BioTELA | 0.2% | $1m | 1,441,029 | Held |
| PolyPidPYPD | 0.2% | $1m | 207,900 | Held |
| Corbus Pharmaceuticals HoldingsCRBP | 0.2% | $1m | 107,773 | New |
| Inspire Medical SystemsINSP | 0.2% | $811,902 | 18,200 | Held |
| Adicet BioACET | 0.2% | $810,536 | 93,812 | Held |
| Seaport TherapeuticsSPTX | 0.1% | $703,728 | 32,400 | New |
| MBX BiosciencesMBX | 0.1% | $651,857 | 11,809 | -93% |
| Biontech SEBNTX | 0.1% | $651,350 | 7,000 | Held |
| Artiva BiotherapeuticsARTV | 0.1% | $650,880 | 67,101 | New |
| Pliant TherapeuticsPLRX | 0.1% | $555,180 | 487,000 | Held |
| ScynexisSCYX | 0.1% | $552,983 | 135,868 | New |
| Editas MedicineEDIT | 0.1% | $552,323 | 170,470 | New |
| Orchestra BioMed HoldingsOBIO | 0.1% | $547,319 | 126,841 | Held |
| Foghorn TherapeuticsFHTX | 0.1% | $545,872 | 111,859 | Held |
| AccurayARAY | <0.1% | $433,235 | 1,680,508 | Held |
| Q32 BioQTTB | <0.1% | $419,095 | 32,896 | New |
| Nuvectis PharmaNVCT | <0.1% | $367,800 | 20,000 | New |
| CompugenCGEN | <0.1% | $360,016 | 168,232 | -35% |
| iBioIBIO | <0.1% | $297,593 | 170,053 | -12% |
| Autolus TherapeuticsAUTL | <0.1% | $286,906 | 179,316 | Held |
| Bicycle TherapeuticsBCYC | <0.1% | $273,446 | 64,492 | Held |
| Tenaya TherapeuticsTNYA | <0.1% | $221,730 | 300,000 | New |
| Verrica PharmaceuticalsVRCA | <0.1% | $145,350 | 23,750 | -85% |
| enGene TherapeuticsENGN | <0.1% | $129,145 | 74,650 | New |
| KardiganKARD | <0.1% | $119,250 | 5,000 | New |
| ADC Therapeutics SAADCT | <0.1% | $82,477 | 77,081 | +7% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 46.8% since 30 June 2025.
Where the money is
Health care90.5%
Other9.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.